Amplification primer group and probe for asthma individualized medication gene detection, detection kit and use method

Abstract

The invention discloses an amplification primer group and a probe for asthma individualized medication gene detection, a detection kit and a use method. The amplification primer group and the probe comprise an ADRB2-rs1042713 wild type forward primer ADRB2F1, an ADRB2-rs1042713 mutant type forward primer ADRB2F2, an ADRB2-rs1042713 common reverse primer ADRB2R, an ADRB2-rs1042713 common probe ADRB2P, an ADRB2F mutant type forward primer ADRB2F, an ADRB2F mutant type forward primer ADRB2F, an ADRB2F mutant type forward primer ADRB2F, an ADRB2F mutant type forward primer ADRB2F, an ADRB2F mutant type The primer set is characterized in that a forward primer GLCCI1F1 of GLCCI1-rs37973, a forward primer GLCCI1F2 of a mutant type of GLCCI1-rs37973, a reverse primer GLCCI1R of GLCCI1-rs37973 and a probe GLCCI1P are shared by the GLCCI1-rs37973, the forward primer GLCCI1F1 of the mutant type of GLCCI1-rs37973 and the forward primer GLCCI1F2 of the mutant type of GLCCI1-rs37973 share the reverse primer The detection method comprises the following steps of: detecting a wild type forward primer CRHR2F1 of CRHR2-rs7793837, a mutant type forward primer CRHR2F2, a common reverse primer CRHR2R and a common probe CRHR2P; the amplification primer group has good amplification specificity, high detection sensitivity, short detection time and low detection cost.

Description

technical field [0001] The present application belongs to the technical field of genetic engineering, and in particular relates to an amplification primer set and a probe, a detection kit and a method of use for gene detection of individualized medication for asthma. Background technique [0002] Asthma, also known as wheezing, is a common chronic inflammatory disease of the airways characterized by variable and recurrent symptoms, reversible airflow obstruction, and bronchospasm. Common symptoms are wheezing, coughing, chest tightness, chest tightness, and difficulty breathing. Statistics show that in 2018, the prevalence of asthma among people over 20 years old in my country was 4.2%, the total number of patients was 45.7 million, and more than 70% of the patients were undiagnosed. [0003] At present, there is no specific method for the treatment of asthma, but long-term standardized treatment can keep asthma symptoms under good control and reduce recurrence or even no m...

AI Technical Summary

Problems solved by technology

For example, the Chinese patent CN113215245A discloses a gene detection kit for individualized medication for children with asthma and its application. Through the method of next-generation sequencing, 31 genes related to individualized medication for children with asthma are detected. Although the accuracy of the method is High, but the timeliness is poor, the cost is high, and the testing items are relatively redundant

In addition, Chinese patent CN109837339A discloses primer sets, probe sets, kits and methods for the detection of genes related to child safety drug use. The polymorphism of the GLCCI1 rs37973 site was detected by the TaqMAN-MGB probe typing technology, although the The method is simple and fast, but it only detects one site related to asthma medication, which is not comprehensive enough

Images